Pembrolizumab: A Review in Advanced Melanoma

被引:0
作者
Emma D. Deeks
机构
[1] Springer,
来源
Drugs | 2016年 / 76卷
关键词
Melanoma; Overall Survival; Ipilimumab; Overall Response Rate; Advanced Melanoma;
D O I
暂无
中图分类号
学科分类号
摘要
Pembrolizumab (Keytruda®) is a humanized monoclonal antibody against programmed death receptor-1 (PD-1), a key immunoinhibitory checkpoint protein implicated in down-regulating anti-tumour immune responses. This intravenous drug is indicated for the treatment of advanced (unresectable or metastatic) melanoma, on the basis of its clinical benefit in this setting in the phase I KEYNOTE 001 trial (expansion cohorts) and the phase II and III trials, KEYNOTE 002 and 006. These studies were conducted in ipilimumab-naïve and/or ipilimumab-experienced patients and assessed varying pembrolizumab regimens administered every 2 or 3 weeks, all of which helped to determine the recommended dosage of 2 mg/kg every 3 weeks. In the trials with active comparator arms, pembrolizumab regimens significantly improved progression-free survival (PFS), overall survival (OS) and overall response rates (ORR) relative to ipilimumab in ipilimumab-naïve patients (KEYNOTE 006), and significantly improved PFS and ORR, but not OS (although OS data are immature), relative to chemotherapy in ipilimumab-refractory patients, who had also received BRAF/MEK inhibitor therapy if BRAF-mutation positive (KEYNOTE 002). Pembrolizumab has an acceptable tolerability profile, with immune-related adverse events that are generally manageable/reversible. Thus, pembrolizumab is a valuable treatment option for patients with advanced melanoma, including those who have progressed on ipilimumab and BRAF/MEK inhibitors.
引用
收藏
页码:375 / 386
页数:11
相关论文
共 50 条
  • [21] Higher BMI, But Not Sarcopenia, Is Associated With Pembrolizumab-related Toxicity in Patients With Advanced Melanoma
    Hu, Janice B.
    Ravichandran, Surya
    Rushing, Christel
    Beasley, Georgia M.
    Hanks, Brent A.
    Jung, Sin-Ho
    Salama, April K. S.
    Ho, Lisa
    Mosca, Paul J.
    ANTICANCER RESEARCH, 2020, 40 (09) : 5245 - 5254
  • [22] Efficacy of pembrolizumab for advanced/metastatic melanoma: a meta-analysis
    Zhang, Qi
    Huo, Geng-wei
    Zhang, Hong-zhen
    Song, Ying
    OPEN MEDICINE, 2020, 15 (01): : 447 - 456
  • [23] 5-year results for pembrolizumab treatment of advanced melanoma
    Hassel, Jessica C.
    LANCET ONCOLOGY, 2019, 20 (09) : 1187 - 1189
  • [24] Safety of pembrolizumab for the treatment of melanoma
    Martin-Liberal, Juan
    Kordbacheh, Tiana
    Larkin, James
    EXPERT OPINION ON DRUG SAFETY, 2015, 14 (06) : 957 - 964
  • [25] Correlation between previous treatment with BRAF inhibitors and clinical response to pembrolizumab in patients with advanced melanoma
    Simeone, Ester
    Grimaldi, Antonio Maria
    Festino, Lucia
    Giannarelli, Diana
    Vanella, Vito
    Palla, Marco
    Curvietto, Marcello
    Esposito, Assunta
    Palmieri, Giuseppe
    Mozzillo, Nicola
    Ascierto, Paolo Antonio
    ONCOIMMUNOLOGY, 2017, 6 (03):
  • [26] Pembrolizumab for advanced melanoma: experience from the Spanish Expanded Access Program
    M. González-Cao
    A. Arance
    J. M. Piulats
    I. Marquez-Rodas
    J. L. Manzano
    A. Berrocal
    G. Crespo
    D. Rodriguez
    E. Perez-Ruiz
    M. Berciano
    A. Soria
    A. G. Castano
    E. Espinosa
    C. Montagut
    L. Alonso
    T. Puertolas
    C. Aguado
    M. A. Royo
    R. Blanco
    J. F. Rodríguez
    E. Muñoz
    P. Mut
    F. Barron
    S. Martin-Algarra
    Clinical and Translational Oncology, 2017, 19 : 761 - 768
  • [27] Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma
    Ribas, Antoni
    Hamid, Omid
    Daud, Adil
    Hodi, F. Stephen
    Wolchok, Jedd D.
    Kefford, Richard
    Joshua, Anthony M.
    Patnaik, Amita
    Hwu, Wen-Jen
    Weber, Jeffrey S.
    Gangadhar, Tara C.
    Hersey, Peter
    Dronca, Roxana
    Joseph, Richard W.
    Zarour, Hassane
    Chmielowski, Bartosz
    Lawrence, Donald P.
    Algazi, Alain
    Rizvi, Naiyer A.
    Hoffner, Brianna
    Mateus, Christine
    Gergich, Kevin
    Lindia, Jill A.
    Giannotti, Maxine
    Li, Xiaoyun Nicole
    Ebbinghaus, Scot
    Kang, S. Peter
    Robert, Caroline
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2016, 315 (15): : 1600 - 1609
  • [28] Association Between Pembrolizumab-related Adverse Events and Treatment Outcome in Advanced Melanoma: Results From the Dutch Expanded Access Program
    Bisschop, Cornelis
    Wind, Thijs T.
    Blank, Christian U.
    Koornstra, Rutger H. T.
    Kapiteijn, Ellen
    Van den Eertwegh, Alfonsus J. M.
    De Groot, Jan Willem B.
    Jalving, Mathilde
    Hospers, Geke A. P.
    JOURNAL OF IMMUNOTHERAPY, 2019, 42 (06) : 208 - 214
  • [29] Nivolumab: A Review in Advanced Melanoma
    Scott, Lesley J.
    DRUGS, 2015, 75 (12) : 1413 - 1424
  • [30] Brain metastasis in a patient with melanoma receiving Pembrolizumab therapy A case report and review of the literature
    Song, Jin-cheng
    Ding, Xiao-lei
    Sun, Xiu-hua
    Safi, Mohammed
    MEDICINE, 2017, 96 (50)